Maferinyah | Labé | |||
---|---|---|---|---|
ASAQ | AL | ASAQ | AL | |
Enrolled | 107 | 104 | 105 | 105 |
Reached study outcome | 105 | 101 | 104 | 103 |
Treatment failure | 5 (5) | 8 (8) | 3 (3) | 6 (6) |
Early treatment failure | 0 | 0 | 0 | 0 |
Late treatment failure | 5 (5) | 8 (8) | 3 (3) | 6 (6) |
Recrudescence | 0 | 0 | 1 (1) | 1 (1) |
Day 28 | 0 | 0 | 1 (1) | 1 (1) |
Reinfection | 5 (5) | 8 (8) | 2 (2) | 5 (5) |
Day 21 | 1 (1) | 3 (3) | 1 (1) | 1 (1) |
Day 28 | 4 (4) | 5 (5) | 1 (1) | 4 (4) |
Adequate clinical and parasitological response | 100 (95) | 93 (92) | 101 (97) | 97 (94) |
Kaplan–Meier Day 28 efficacy | ||||
Uncorrected | 95.2% (91.3–99.4) | 92.1% (87.1–97.5) | 97.1% (94–100) | 94.2% (89.9–98.8) |
Microsatellite-corrected | 100%a | 100%a | 99% (97.2–100) | 99% (97.1–100) |